Wanjing Feng1,2, Yue Wang2,3, Xiaodong Zhu1,2. 1. Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China. 2. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China. 3. Department of Urology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Abstract
BACKGROUND: Bevacizumab, a humanized monoclonal antibody against vascular epithelial growth factor, plays a significant role in first-line, second-line, beyond-progression, and maintenance treatment of patients with metastatic colorectal carcinoma (mCRC). Nevertheless, there are currently no biomarkers available to predict patient response or resistance to bevacizumab, which would be useful in clinical trials. METHODS: Using PRISMA guidelines, we conducted a systematic review and meta-analysis of the association between serum lactate dehydrogenase (LDH) level and progression-free survival (PFS), overall survival (OS), and objective response rate in mCRC patients treated with bevacizumab-based first-line chemotherapy. A comprehensive, computerized literature search of PubMed, the Web of Science, Scopus, Ovid, and the gray literature was performed. Only studies conforming to specific eligibility criteria were included. Pooled hazard ratios (HRs) were estimated using random-effects or fixed-effects models according to heterogeneity between studies. Sensitivity analysis was conducted to evaluate the stability of the results by removing each individual study from the meta-analysis. RESULTS: Seven eligible studies of 1,219 total patients were included in the analysis. Meta-analysis of all studies revealed that high serum LDH level is associated with shorter PFS (HR: 1.43, 95% CI: 1.05-1.94; P=0.023) and OS (HR: 1.667, 95% CI: 1.230-2.259; P=0.001) times in mCRC patients treated with bevacizumab-based first-line chemotherapy. However, there was no significant association between serum LDH and objective response rate. CONCLUSIONS: High serum LDH level is significantly associated with shorter PFS and OS time and may have utility as a prognostic factor for mCRC patients receiving bevacizumab as first-line chemotherapy and as a predictive factor for those receiving bevacizumab-based therapy at other times.
BACKGROUND: Bevacizumab, a humanized monoclonal antibody against vascular epithelial growth factor, plays a significant role in first-line, second-line, beyond-progression, and maintenance treatment of patients with metastatic colorectal carcinoma (mCRC). Nevertheless, there are currently no biomarkers available to predict patient response or resistance to bevacizumab, which would be useful in clinical trials. METHODS: Using PRISMA guidelines, we conducted a systematic review and meta-analysis of the association between serum lactate dehydrogenase (LDH) level and progression-free survival (PFS), overall survival (OS), and objective response rate in mCRC patients treated with bevacizumab-based first-line chemotherapy. A comprehensive, computerized literature search of PubMed, the Web of Science, Scopus, Ovid, and the gray literature was performed. Only studies conforming to specific eligibility criteria were included. Pooled hazard ratios (HRs) were estimated using random-effects or fixed-effects models according to heterogeneity between studies. Sensitivity analysis was conducted to evaluate the stability of the results by removing each individual study from the meta-analysis. RESULTS: Seven eligible studies of 1,219 total patients were included in the analysis. Meta-analysis of all studies revealed that high serum LDH level is associated with shorter PFS (HR: 1.43, 95% CI: 1.05-1.94; P=0.023) and OS (HR: 1.667, 95% CI: 1.230-2.259; P=0.001) times in mCRC patients treated with bevacizumab-based first-line chemotherapy. However, there was no significant association between serum LDH and objective response rate. CONCLUSIONS: High serum LDH level is significantly associated with shorter PFS and OS time and may have utility as a prognostic factor for mCRC patients receiving bevacizumab as first-line chemotherapy and as a predictive factor for those receiving bevacizumab-based therapy at other times.
Entities:
Keywords:
Lactate dehydrogenase (LDH); bevacizumab; colorectal cancer
Authors: D M Brizel; T Schroeder; R L Scher; S Walenta; R W Clough; M W Dewhirst; W Mueller-Klieser Journal: Int J Radiat Oncol Biol Phys Date: 2001-10-01 Impact factor: 7.038
Authors: Bulent Cetin; Mehmet Ali Kaplan; Veli Berk; Selcuk Cemil Ozturk; Mustafa Benekli; Abdurrahman Isıkdogan; Metin Ozkan; Ugur Coskun; Suleyman Buyukberber Journal: Asian Pac J Cancer Prev Date: 2012
Authors: J Randolph Hecht; Tanja Trarbach; John D Hainsworth; Pierre Major; Elke Jäger; Robert A Wolff; Katherine Lloyd-Salvant; György Bodoky; Kelly Pendergrass; William Berg; Bee-Lian Chen; Tarja Jalava; Gerold Meinhardt; Dirk Laurent; David Lebwohl; David Kerr Journal: J Clin Oncol Date: 2011-04-04 Impact factor: 44.544
Authors: Eric Van Cutsem; Emilio Bajetta; Juan Valle; Claus-Henning Köhne; J Randolph Hecht; Malcolm Moore; Colin Germond; William Berg; Bee-Lian Chen; Tarja Jalava; David Lebwohl; Gerold Meinhardt; Dirk Laurent; Edward Lin Journal: J Clin Oncol Date: 2011-04-04 Impact factor: 44.544
Authors: Leonard B Saltz; Stephen Clarke; Eduardo Díaz-Rubio; Werner Scheithauer; Arie Figer; Ralph Wong; Sheryl Koski; Mikhail Lichinitser; Tsai-Shen Yang; Fernando Rivera; Felix Couture; Florin Sirzén; Jim Cassidy Journal: J Clin Oncol Date: 2008-04-20 Impact factor: 44.544
Authors: Mizutomo Azuma; Michael Shi; Kathleen D Danenberg; Humphrey Gardner; Carl Barrett; Christian J Jacques; Andrew Sherod; Syma Iqbal; Anthony El-Khoueiry; Dongyun Yang; Wu Zhang; Peter V Danenberg; Heinz-Josef Lenz Journal: Pharmacogenomics Date: 2007-12 Impact factor: 2.533
Authors: M Scartozzi; R Giampieri; E Maccaroni; M Del Prete; L Faloppi; M Bianconi; E Galizia; C Loretelli; L Belvederesi; A Bittoni; S Cascinu Journal: Br J Cancer Date: 2012-02-07 Impact factor: 7.640
Authors: Eduardo Díaz-Rubio; Auxiliadora Gómez-España; Bartomeu Massutí; Javier Sastre; Margarita Reboredo; José Luis Manzano; Fernando Rivera; M José Safont; Clara Montagut; Encarnación González; Manuel Benavides; Eugenio Marcuello; Andrés Cervantes; Purificación Martínez de Prado; Carlos Fernández-Martos; Antonio Arrivi; Inmaculada Bando; Enrique Aranda Journal: PLoS One Date: 2012-10-12 Impact factor: 3.240